1st International Standard for HIV-1 RNA NIBSC Code 97/656

Slides:



Advertisements
Similar presentations
Preparation, characterization and establishment of a WHO International Biological Reference Preparation Dr Sjoerd Rijpkema Division of Bacteriology NIBSC.
Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section
Marta José, Instituto Grifols S.A., Barcelona, SPAIN
Replacement of the 1 st Parvovirus B19 DNA International Standard SoGAT XXI, Brussels, 28th-29th May 2009 Sally Baylis.
Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
NIBSC Multiplex Proficiency Panel - A multicentre study
XX. SoGAT Meeting Warsaw 12./13. June 2007 IU vs. NAT-Detectable Units Albrecht Gröner CSL Behring Virology Marburg, Germany.
Development of an HIV-2 RNA International Standard Harvey Holmes, Clare Morris, Neil Berry, Alan Heath and Collaborative Study Group.
Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Paris, May 2004SoGAT XVII SoGAT and the Development of Standards Harvey Holmes Division of Retrovirology NIBSC, UK.
Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:
Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA
XVIII SoGAT Washington 24 May 2005 SoGAT and HIV NAT Standards - 2 nd International Standard for HIV-1 RNA Harvey Holmes*, Clare Davis* and Alan Heath**
Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
BioLife Plasma Services Experience with HBV NAT Testing
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.
Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007.
SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Standardization – CBER update June 12, 2007 XX SoGAT Indira Hewlett, Ph.D. Chief, Lab. of Molecular Virology DETTD/CBER/FDA.
EQASs for Blood Borne Virus Genomes and BSE Prions from Cattle Brain and INSTAND Reference Materials H.-P. Grunert 1,2, K.-O. Habermehl 1,2, V. Lindig.
Standardisation of P. falciparum HBV, HCV and NAT Sally Baylis, NIBSC SoGAT XVIII.
Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.
Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.
SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,
1 Procleix ® WNV Assay: A TMA-based Assay for Screening Blood Donations for West Nile Virus RNA Jeff Linnen, Ph.D. Research and Development Gen-Probe Incorporated,
National Institute for Biological Standards and Control Assuring the quality of biological medicines Human Cytomegalovirus (HCMV) Proposed 1 st International.
Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.
SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.
Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.
Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.
Performance of Chiron Quantitative and Qualitative HBV PCR Assay and Confirmation of HBV Yield Cases Yiu-Lian Fong, Ph.D, Associate Director June 13, 2007.
A multi-centre NAT evaluation study of run and trend control samples Harry van Drimmelen 1, Joe O’Donnellan 2, Rene Bax 1, Henrik Ullum 3 and the Danish.
NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.
Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.
An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.
E B—Anti-HBc Chart 1 10/2004 Anti-HBc Testing and Donor Reentry Results of a Pilot Study Susan L. Stramer, Ph.D. American Red Cross Blood Products.
CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.
SoGAT May 2005 Are conversion factors to international units assay related? Marco Koppelman, Henk Reesink, Nico Lelie, Theo Cuypers.
Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.
HBV DNA Quantification: Results from the UK NEQAS Proficiency Panel
Cepheid Symposium IAS 2017 Gwynn Stevens, PhD Director of Virology
Saeko Mizusawa, Yoshiaki Okada
Ann Intern Med. 2017;167(1):1-7. doi: /M Figure Legend:
Human Parvovirus PARV4 in Blood and Plasma Products
GRIFOLS PLASMA: genotype 2 vB19 sample
Testing for Parvovirus B19 - Broadening the Assay to Cover Variants
Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology
Standardization of Sample Preparation for NAT
Results of Recent EQA Panels for Blood Borne Viruses
Tom Øystein Jonassen, Mona Holberg-Petersen, Einar S. Berg
Characterisation of HBV DNA in reference preparations
Chronic Hepatitis C Therapy: Changing the Rules of Duration
In Vivo Tropism of Hepatitis C Virus Genomic Sequences in Hematopoietic Cells: Influence of Viral Load, Viral Genotype, and Cell Phenotype by Hervé Lerat,
Roche Molecular Diagnostics
Update on CBER HIV-1 Subtype panel
Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test Lutz Pichl, Volkmar Schottstedt German Red Cross Blood Transfusion.
Evaluation of Candidate Standard XX (97/650)
K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003
High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric.
Feasibility of Synthetic Materials as Primary Standards
Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K
Viral Safety of Blood Products in Taiwan
Volume 5, Issue 6, Pages (June 2002)
SoGAT Meeting, Berne, 14 June 2006 M. Nübling (PEI, Germany)
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Evaluation of the Abbott Investigational Use Only RealTime HIV-1 Assay and Comparison to the Roche Amplicor HIV-1 Monitor Test, Version 1.5  Michael T.
SoGAT meeting XXI May (2009), Brussels, Belgium
Presentation transcript:

1st International Standard for HIV-1 RNA NIBSC Code 97/656 CBER, CLB and NIBSC collaborated in development of HIV-1 International Standard for NAT Three candidate standards evaluated in collaborative study WHO Expert Committee (ECBS) established candidate YY as 1st International Standard for HIV-1 RNA (code 97/656) Assigned a concentration of 100,000 IU per vial/ml (1IU ~ 0.58 copies/ml) YY was human HIV-1-positive plasmapheresis donation diluted in defibrinated plasma Has recently been found positive for HBV DNA WHO Expert Committee (ECBS) established candidate YY as 1st International Standard for HIV-1 RNA (code 97/656) Assigned a concentration of 100,000 IU per vial/ml Mean copy number in 20 quantitative assays was: 4.75 Log10 RNA copies/ml 56,000 RNA copies/ml 1 RNA copy equal to 1.78 IU Available from NIBSC 03 July 2003 SoGAT XVI

1st International Standard for HIV-1 RNA Code 97/656 In-house qualitative assay detected HBV DNA (David Padley, NIBSC) Nested PCR positive for HBV DNA – estimated viral load at 3.5 x 104 amplifiable copies/ml (Alison Hardie, University of Edinburgh) Procleix Triplex assay showed that 100 IU/ml dilution of HIV-1 International Standard contains 611 IU/ml HBV DNA (V Shyamala, Chiron Corporation) What are the implications of this? 03 July 2003 SoGAT XVI

1st International Standard for HIV-1 RNA: Implications of HBV Contamination For use in monovalent HIV-1 NAT or multivalent NAT assays that do not include HBV detection: International Standard may still be used as directed For use in multiplex assays that detect both HIV-1 RNA and HBV DNA : 1st international Standard for HIV-1 may not be suitable for the quantitation of HIV-1 RNA What difficulties will this cause for users? Do we need to establish a second International Standard calibrated on the first? If so, should we use candidate XX used in the collaborative study? 03 July 2003 SoGAT XVI

Development of 1st International Standard for HIV-1 RNA Candidate: XX YY Subtype: B Virus: Primary isolate Plasmapheresis donation Propagated: PBMCs No Copy number: High Medium Freeze-dried: Yes Diluent: Plasma Volume: 1ml 03 July 2003 SoGAT XVI

Development of 1st International Standard for HIV-1 RNA Candidate XX Candidate YY Candidate ZZ --- bDN --- Monitor --Nuclisens --- Abbott --- in-house 03 July 2003 SoGAT XVI

Distribution: Approx 240 vials/year On present trend, Std will run out in 4 years, possibly sooner 03 July 2003 SoGAT XVI

1st International Standard for HIV-1 RNA: Implications of HBV Contamination If it is agreed that candidate XX be brought in as a replacement for 1st international Standard (YY) we will need to carry out small comparability and stability study to confirm that performance is satisfactory This can be carried out over next 6 months in time for approval at WHO ECBS meeting in 2004 03 July 2003 SoGAT XVI